ADC Therapeutics SA, based in Lausanne, Switzerland, has announced the issuance of stock options to two new employees as part of its Inducement Plan. On June 2, 2025, the company granted options to purchase a total of 107,550 common shares. These grants were approved by the Compensation Committee and are structured to vest over a four-year period. Initially, 25% of the options will become exercisable on the first anniversary of the grant date, with an additional 1/48th of the shares vesting monthly thereafter, contingent upon continued employment with the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.